Home
Applications
Indications
Business
EpiSwitch
®
Products
EpiSwitch
®
Checkpoint Inhibitor Response Test
EpiSwitch
®
COVID-19 Severity Test
EpiSwitch
®
Explorer Array Kit
EPISWITCH
®
ANALYTICAL PORTAL
EpiSwitch
®
Service
Investors
Investors Overview
Results and Presentations
Share Price Information
Regulatory News
Board & Governance
Key Corporate Documents
AIM Rule 26
Email Alerts
Investor Contacts
News
About Us
History
Board of Directors
Management Team
Scientific Advisory Panel
Values
Careers
Contact Us
Milestones
EpiSwitch
®
CiRT now available in the UK
Press Release
by Aroul Ramadass
Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) for oncology launched in US
Press Release
by Aroul Ramadass
OBD updates on EpiSwitch CST and CiRT tests
Press Release
by oxfordbiodynamics
Circular to Shareholders 26 October 2021
Press Release
by oxfordbiodynamics
EpiSwitch® used in diagnosis of canine lymphoma
Press Release
by Aroul Ramadass
Oxford Biodynamics Plc enters into master service agreement with world leading US pharmaceutical company to evaluate EpiSwitch™ biomarkers
Press Release
by oxfordbiodynamics
OBD joins ALS Biomarker study sponsored by Mitsubishi Tanabe Pharma America
Press Release
by oxfordbiodynamics
Oxford BioDynamics receives Queen's Award for Enterprise
Press Release
by oxfordbiodynamics
Oxford BioDynamics joins Imperial College London in a trial evaluating novel methods of screening for prostate cancer
Press Release
by oxfordbiodynamics
Collaboration agreement with Casa Sollievo della Sofferenza signed for the blood-based diagnosis of Autism Spectrum Disorder
Press Release
by Aroul Ramadass
1
2
3
…
14
Privacy Preference Center
Privacy Preferences
